274: Covid’s latest surge, Alnylam at the FDA, & the end of an era
The Readout Loud
00:00
Bluebird Bio Restructuring Announcement
This chapter discusses the recent restructuring announcement made by Bluebird Bio / 270 Bio, including the reduction in force and exit of their CEO. It highlights the challenges faced by Bluebird Bio and 270 Bio in the oncology field, along with the rapid advancements in gene therapies and genome editing.
Transcript
Play full episode
